CBIO - NASDAQ
Crescent Biopharma, Inc.
$18.45
+8.5%Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
At a Glance
Live Snapshotcbio
Total Liabilities and Equity
Last Annual Value
240.29M
3-Year CAGR
67%
5-Year CAGR
11%
10-Year CAGR
17%
Crescent Biopharma, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Crescent Biopharma, Inc. NASDAQ:CBIO | 240.29M | 74.4% | 20.6% | 18.9% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 122.83M | -26.6% | -11.8% | N/A | |
 Anixa Biosciences, Inc. NASDAQ:ANIX | 16.08M | -14.3% | -15.0% | 11.1% | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 61.88M | -8.8% | -16.2% | 3.5% | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 3.81M | -18.4% | -32.5% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 173.91M | 6.7% | 3.9% | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 3.46M | -14.3% | -14.7% | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 76.88M | -7.9% | 2.0% | 15.5% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 59.74M | -28.8% | -39.2% | -9.3% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 359.07M | -1.6% | -6.7% | N/A | |
 Heron Therapeutics, Inc. NASDAQ:HRTX | 255.88M | 4.8% | -3.5% | 14.3% |
Crescent Biopharma, Inc. Fair Value Envelope
Related Guides
Continue your CBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.